Simvastatin treatment reduces the cholesterol content of membrane/lipid rafts, implicating the N-methyl-D-aspartate receptor in anxiety: a literature review

Júlia Niehues da Cruz¹, Débora Delwing Dal Magro², Daniela Delwing de Lima³, José Geraldo Pereira da Cruz²*

¹Instituto Dante Pazzanese de Cardiologia, São Paulo, SP, Brasil, ²Universidade Regional de Blumenau, Blumenau, SC, Brasil, ³Universidade da Região de Joinville, Joinville, SC, Brasil

Membrane/lipid rafts (MLRs) are plasmalemmal microdomains that are essential for neuronal signaling and synaptic development/stabilization. Inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase (statins) can disable the N-methyl-D-aspartate (NMDA) receptor through disruption of MLRs and, in turn, decrease NMDA-mediated anxiety. This hypothesis will contribute to understanding the critical roles of simvastatin in treating anxiety via the NMDA receptor.

**Uniterms:** Anxiolytic effects. Membrane/lipid rafts. N-methyl-D-aspartate. Simvastatin.

**INTRODUCTION**

Clinically, simvastatin (SIM) has been widely used to reduce serum low-density lipoprotein (LDL) cholesterol levels by inhibiting the rate-limiting enzyme 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) reductase (Owens, Byrnes, Mackman, 2014). However, SIM also has pleiotropic effects, such as anti-inflammatory, antioxidative and immunomodulatory effects (Eger et al., 2016a, 2016b; Mihos, Pineda, Santana, 2014; Ungureanu et al., 2003). Evidence illustrates that SIM reduces the risk of ischemic heart disease and cerebrovascular stroke and that it has potential applications in multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease (Daneschvar, Aronson, Smetana, 2015; Friedman et al., 2013; Kataoka et al., 2015; Ní Chróinín et al., 2013; Pihl-Jensen, Tsakiri, Frederiksen, 2015; Sett, Robinson, Mistri, 2011). Despite growing evidence for the role of SIM in treating central nervous system (CNS) diseases, there is relatively little knowledge of its direct psychoneurological effects on central receptors and its association with behavioral effects.

In the CNS, cellular cholesterol homeostasis is independent of plasma cholesterol levels because blood-to-brain cholesterol transport is virtually nonexistent through the blood-brain barrier (Chobanian, Hollander, 1962; Dietzsch, Turley, 2004). Statins that cross the blood-brain barrier could disrupt normal cholesterol turnover. As such, SIM, as a lipophilic statin that can cross the blood-brain barrier easily, was recommended as the best candidate capable disrupting CNS cholesterol homeostasis (Lutjohann et al., 2004; Thelen et al., 2006). Changes in brain cholesterol metabolism have been reported in experimental animals and humans. 24(S)-Hydroxycholesterol has been used in many studies as an indicator of brain cholesterol turnover, as it is the by-product of cholesterol metabolism through brain-selective cholesterol 24-hydroxylase (CYP46A1) and is capable of crossing the blood-brain barrier for detection in systemic circulation. Following chronic SIM administration, numerous studies identified reductions in the plasma and cerebrospinal fluid concentrations of 24(S)-hydroxycholesterol (Locatelli et al., 2002; Serrano-Pozo et al., 2010; Thelen et al., 2006). This is in-line with reduced cholesterol elimination in the brain as a result of prolonged statin treatment and suggests that statins affect cholesterol homeostasis in the brain. However, although the effect of SIM on the peripheral pool of cholesterol is well-established, its effects on CNS cholesterol are less clear.
There are literature data demonstrating that SIM treatment diminished cholesterol levels in the brain and protected neurons in vitro against cell death induced by excessive stimulation of NMDA receptors (Kirsch, Eckert, Mueller, 2003; Zacco et al., 2003). NMDA receptors have been reported to be associated with cholesterol-rich membrane microdomains known as membrane/lipid rafts (MLRs) that bind specific proteins (Nothdurfter et al., 2013). MLRs have been proposed to function as platforms that allow the local accumulation of raft-associated proteins, promoting interactions among protein complexes and modulating neurotransmitter signaling (Allen, Halverson-Tamboli, Rasenick, 2007; Resh, 2004). Accumulating evidence indicates that the precise localization of neurotransmitter receptors, transporters, ion channels, and other synaptic proteins in MLRs can be regulated by cholesterol and this regulation is critical for synaptic plasticity (Allen, Halverson-Tamboli, Rasenick, 2007; Sebastião et al., 2013). Due to its impact on cholesterol synthesis and protein modification, SIM perturbs the composition and properties of MLRs (van der Most et al., 2009). Thus, treatment with SIM might affect the functionality of proteins associated with MLRs, such as NMDA receptors (Ponce et al., 2008). In fact, alterations in MLRs composition and structure have been associated with different pathologies, and therefore, drug-induced regulation of MLRs composition and structure can modulate cell signaling, offering potentially effective treatments for a variety of conditions (Escribá et al., 2015; Marin et al., 2013; Michel, Bakovic, 2007).

Our hypothesis provides strong evidence that NMDA receptor modulation after SIM treatment could be associated with cholesterol-rich membrane microdomains. It is well documented that NMDA receptors in the brain have a close correlation with anxiety-like activity (Bergink, van Megen, Westenberg, 2004; Chojnacka-Wójcik, Klodzinska, Pilec, 2001). Modulation of NMDA receptors activity after SIM treatment could explain the drug’s anxiolytic-like effects (Camargo et al., 2013; Carrocini et al., 2012; Cruz et al., 2011; Kilic et al., 2012; Pauletí et al., 2013; Santos et al., 2012; Wang et al., 2009; Yan et al., 2011). This hypothesis could be supported by the fact that altered levels of NMDA receptors in the hippocampus and amygdala directly influence anxiety behaviors (Barkus et al., 2010; Blundell, Adamec, 2007; Masneuf et al., 2014).

**CHOLESTEROL IN THE CNS**

Balanced cholesterol homeostasis is an important aspect of nervous system function (Mathews et al., 2014). The majority of cholesterol is present in myelin sheaths and neuronal membranes, in which this lipid fulfills structural and functional tasks. Given the crucial role of cholesterol in regulating different neuronal processes, eukaryotes have developed sophisticated homeostatic mechanisms to preserve cholesterol levels in an optimal range in each brain region (Saheer, Stumpf, 2015; Segatto et al., 2013). Largely, cholesterol in the adult brain is metabolically inert. The most significant period of high cholesterol synthesis in the CNS occurs during active myelination, which occurs in early neural development through the action of oligodendrocytes (Dietschy, Turley, 2004). The rate of cholesterol synthesis decreases significantly after myelination has been completed; however, its synthesis continues at a low basal level in the mature adult brain. This occurs primarily through de novo cholesterol synthesis by astrocytes, although neuronal de novo synthesis and reutilization of free cholesterol following neuronal death are also contributory (Nieweg, Schaller, Pfrieger, 2009). Therefore, the CNS does not rely largely on cholesterol from systemic circulation due to limited metabolic turnover during adulthood and the brain’s inherent capacity to synthesize its own cholesterol (Dietschy, Turley, 2004). Consequently, reductions in plasma cholesterol concentrations following statin treatment are unlikely to acutely disrupt in CNS cholesterol homeostasis (Lutjohann et al., 2004; Thelen et al., 2006). Thus, chronic statin therapy may be required before significant effects on CNS cholesterol levels are observed, with reductions in CNS cholesterol possible either directly through direct HMG-CoA reductase inhibition or indirectly via a “sink effect” (Cibičková, 2011). In addition, cholesterol depletion is reported to lead to the inhibition of Ca\(^{2+}\) entry induced by NMDA, α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA), or kainate, inferring that MLRs contribute to the regulation of ionotropic glutamate receptor function (Frank et al., 2008).

**THE CONCEPT OF MLRS/NMDA RECEPTORS**

MLRs consist of assemblies of cholesterol, sphingolipids including sphingomyelin and gangliosides, and certain types of proteins (Fielding, Fielding, 2003). They range from a few nanometers to a few hundred nanometers in diameter and comprise approximately 50% of the cellular membrane (Helms, Zuruolo, 2004). The most important properties of MLRs are that they are small, dynamic, and heterogeneous, and they can include or exclude proteins to variable extents (Hanzal-Bayer, Hancock, 2007; Simons, Toomre, 2000). MLRs have been implicated in various physiological cellular processes, such as protein membrane trafficking and signal transduction,
and they have been demonstrated to play roles in synaptic plasticity and contribute to neuropathologies, such as Alzheimer’s disease, Parkinson’s disease, and Huntington disease (Hanzal-Bayer, Hancock, 2007; Karasinska, Hayden, 2011; Korade, Kenworthy, 2008; Sebastião et al., 2013; Simons, Toomre, 2000). Cholesterol is a key component of MLRs, as its depletion disrupts MLRs and leads to synaptic dysfunction or loss of synapses (Fielding, Fielding, 2003; Korade, Kenworthy, 2008; Sebastião et al., 2013). Cholesterol is responsible for MLRs maintenance in a liquid-ordered phase (Marwali et al., 2003). It maintains the raft assembly together and serves as a molecular spacer between hydrocarbon chains in sphingolipids (Simons, Toomre, 2000). Additionally, the interaction of cholesterol with distinct classes of membrane proteins within MLRs affects the assembly, stability, and function of the proteins (Lee, 2004). The two main types of MLRs in mammalian cells are planar MLRs and caveolae. As their names suggest, planar MLRs are continuous with the membrane, whereas caveolae form invaginations. Apart from their shape, caveolae and planar rafts can be distinguished by their marker proteins, namely: caveolins and flotillin, respectively. Flotillin and caveolins recruit other proteins to the raft, but they are structurally distinct (Allen, Halverson-Tamboli, Rasenick, 2007). The relative proportions of these components vary greatly depending on the cell and membrane type (Epand, 2008; Gallala, Breiden, Sandhoff, 2011). MLRs are specialized membrane structures that form an organized portion of the membrane with concentrated signaling molecules and links to the cytoskeleton (Byrum, Rodgers, 2015). Synapses, including both pre-synaptic and post-synaptic sites, are highly enriched in MLRs. MLRs both contribute to neurotransmitter exocytosis in pre-synaptic terminals, and post-synthetically modulate neuronal signaling through clustering of neurotransmitter receptors, ion channels, and components of downstream effectors. Several studies illustrated that MLRs concentrate many of the regulators and ion channels involved in Ca\(^{2+}\) signaling, suggesting significant roles of MLRs in modulating Ca\(^{2+}\) signaling (Pani, Singh, 2009).

The NMDA receptor is an ionotropic glutamate receptor. Its channel commonly has a high relative permeability to Ca\(^{2+}\), and it is blocked in a voltage-dependent manner by magnesium ions such that at resting potential the response is substantially inhibited. Cholesterol depletion is reported to lead to an inhibition of Ca\(^{2+}\) entry induced by NMDA, AMPA, or kainate, inferring that MLRs contribute to the regulation of ionotropic glutamate receptor function (Egawa et al., 2016; Frank et al., 2008). Numerous post-synaptic density proteins such as NMDA (NR1, NR2A and NR2B), AMPA (GluR1 and GluR2), and metabotropic glutamate receptors (mGluRs) are associated with synaptic MLRs, providing a trans-synaptic link between postsynaptic density proteins and pre-synaptic active zones (Egawa et al., 2016; Kumari, Castillo, Francesconi, 2013). Accumulating evidence suggests that MLRs clustering is a novel mechanism mediating and amplifying transmembrane signaling in response to various stimuli in a variety of cell types, including lymphocytes, endothelial cells, and neurons (Dupree, Pomier, 2010; Grassme et al., 2001; Zhang et al., 2006). These membrane platforms can recruit or aggregate various signaling molecules such as small G proteins, tyrosine kinases, and phosphatases, resulting in the activation of different signaling pathways (Zhang et al., 2009).

**MODULATION OF THE ISOPRENOID/CHOLESTEROL BIOSYNTHETIC PATHWAY**

Statins are the drugs of choice for lowering LDL cholesterol and triglyceride levels in patients with hypercholesterolemia (Owens, Byrnes, Mackman, 2014). The mechanism of action of these drugs is competitive and selective inhibition of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, because it is responsible for the conversion of HMG-CoA to mevalonate, which is a precursor of cholesterol. Although inhibition of HMG-CoA reductase by statins reduces cholesterol synthesis, a concomitant effect of this functional blockade is decreased availability of isoprenoids, the major donors of prenyl groups for protein prenylation. A branch point downstream of mevalonate synthesis draws substrates away from cholesterol synthesis and yields the production of non-sterol isoprenoids such as farnesyl pyrophosphate (FPP), which can be converted into squalene and cholesterol but is also used for the production of geranylglyceranyl pyrophosphate (GGPP), an important component for the localization and function of signaling proteins such as Ras (McTaggart, 2006). Small G-proteins (the Ras superfamily of small GTPases) comprise a large group of molecular switch proteins involved in several signaling pathways, reorganization of the cytoskeleton, and intracellular membrane trafficking. Although FPP and GGPP appear to mediate some of the effects of statins, it is likely that the downstream small GTPase family of signaling molecules also plays an important role (Houten, Frenkel, Waterham, 2003).

The fact that more than 300 proteins have been identified as prenylation targets complicates any prediction of the mechanism by which statins and other prenylation inhibitors affect intracellular signaling. Inhibition of HMG-CoA reductase results in
decreased levels of FPP and GGPP, potentially leading to decreased farnesylation and geranylgeranylation of proteins. Predictions are further confounded by an incomplete understanding of the mechanism by which the farnesylation and geranylgeranylation regulate the vast number of small GTPases in the context of multiple cellular compartments and interacting processes. The small GTPases, which include the two major families Ras and Rho, are differentially regulated by farnesylation and geranylgeranylation, respectively, although some exceptions exist (McTaggart, 2006). By facilitating the coupling of extracellular signals to intracellular kinase activity, both families of GTPases regulate intracellular functions.

The inhibition of farnesylation by SIM has been associated with the enhancement of long-term potentiation between neurons in mice (Mans, McMahon, Li, 2012). This study also found that the protective effect of SIM treatment was abolished following replenishment of FPP but not GGPP. Paradoxically, it has been suggested in other studies that the constant production of GGPP, but not FPP or cholesterol, is required for neurite outgrowth and maintenance, long-term potentiation, and learning, possibly suggesting divergent neuroprotective effects associated with these two isoprenoid intermediates (Kotti et al., 2006). Given the different roles of these compounds, known differences in FPP/GGPP ratios across various brain regions may subsequently result in different local SIM-induced effects within these regions. The mechanisms underlying the differential distribution of FPP and GGPP across the brain and the interplay with the effects of SIM are unknown. However, studies supporting the isoprenoid hypothesis were performed using extremely high statin concentrations; thus, their clinical significance is debatable. The question whether inhibition of prenylation occurs in the brain therefore remains open. We believe that more detailed research into the pharmacology of statins, particularly the concentrations they reach in the CNS and the level at which they block the production of cholesterol and various isoprenoids in different cell types, may solve this question.

However, the impact of SIM treatment on NMDA receptor function/trafficking is most likely related to the effects of SIM on protein prenylation, in particular protein-farnesylation. Indeed, activation of the small GTPase H-Ras, which depends on farnesylation for function, decreases the surface distribution of the NR2 subunit of the NMDA receptor (Suvarna et al., 2005). Ruocco et al. (2007) demonstrated that inhibition of H-Ras farnesylation by farnesyltransferase inhibitor treatment inhibits NMDA-mediated excitotoxicity in the rat brain. By contrast, treatment of hippocampal slices for several hours with SIM increases the magnitude of NMDA receptor-dependent long-term potentiation, a mechanism thought to mediate memory at the cellular level, in the CA1 region in the brains of young adult C57BL/6 mice (Figure 1) (Mans, McMahon, Li, 2012). Additionally, chronic SIM treatment in rats stimulates the production of brain-derived neurotrophic factor in the hippocampus after traumatic brain injury by activating Akt-mediated signaling (Wu et al., 2008), as well as increases NMDA receptor levels, promotes neurogenesis, and increases cerebral blood flow by up-regulating vascular growth factor, synaptophysin, Akt, and ERK (Chen et al., 2003; Wang et al., 2009). However, numerous pre-clinical studies led to the hypothesis that hypofunctional NMDA receptors may also play an important role in the mechanism of anxiolytic actions after SIM treatment (Camargo et al., 2013; Carrocini et al., 2012; Cruz et al., 2011; Pauleti et al., 2013; Santos et al., 2012; Wang et al., 2009; Yan et al., 2011). Accordingly, the functional consequence of such regulation on NMDA receptor function varies on the basis of both the identity of the G protein coupled receptor, and the cell type in which relevant receptors are expressed. Certainly, further studies are needed to identify particular small GTPases and related signaling pathways that mediate the neuronal effects of SIM.

The studies supporting the isoprenoid hypothesis were performed using extremely high statin concentrations, and thus, their clinical significance is debatable. The question whether inhibition of prenylation occurs in the brain therefore remains open. We believe that more detailed research into the pharmacology of statins, particularly the concentrations they reach in the CNS and the level at which they block the production of cholesterol and various isoprenoids in different cell types, may solve this question.

INVolvEMENT OF THE NMDA RECEPTOR COMPLEX IN ANXIOLYTIC-LIKE EFFECTS

The results of a number of studies performed in recent years indicate that glutamatergic neurotransmission

Simvastatin → Farnesyl Pyrophosphate ↓ → H-Ras ↓ → NMDA receptor ↑

**FIGURE 1** - Effects of simvastatin (SIM) on the N-methyl-D-aspartate (NMDA) biosynthesis pathway. Inhibition of H-Ras by SIM suggests increased NMDA receptor levels.
Simvastatin treatment reduces the cholesterol content of membrane/lipid rafts, implicating the N-methyl-D-aspartate receptor in anxiety (Masneuf et al., 2014). The ionotropic glutamate receptor family comprises ligand-gated channels divided into three groups named after their selective agonists, namely NMDA, AMPA, and kainate and their density is high in cortical and limbic regions implicated in the mediation of fear and anxiety (Bergink, van Megen, Westenberg, 2004; Réus et al., 2015). Several binding sites for structurally different ligands have been recognized within the NMDA receptor, including a high affinity site for glutamate and NMDA, a glycine site physiologically activated by glycine or D-serine, and a polyamine site for putrescine, spermine and spermidine (Hirose et al., 2015; Mothet, Le Bail, Billard, 2015; Sirriech, Maclean, Jayaraman, 2015). To activate the NMDA receptor, both glutamate and glycine sites should be occupied simultaneously, and depolarization of the membrane by AMPA receptors at the same synapse is required (Dutta et al., 2015). Under depolarizing conditions, the blockade of ion channels is relieved and the inflow of Na⁺ and Ca²⁺ ions through the NMDA receptor pore is permitted (Seong, Behnia, Carter, 2014). Several studies revealed that MLRs concentrate many of the regulators and ion channels involved in Ca²⁺ signaling, suggesting significant roles of MLRs in modulating Ca²⁺ signaling (Marques-da-Silva, Gutierrez-Merino, 2012, 2014).

Pre-clinical data indicate that a number of different classes of NMDA receptor antagonists, acting at specific sites on the NMDA receptor complex, produced anxiolytic-like activity in tests of anxiety in rodents. It has been reported that a close correlation exists between the regulation of NMDA receptors in the brain and anxiety-like behavior (Bergink, van Megen, Westenberg, 2004). By applying the selective NMDA receptor antagonist (+)-2-amino-5-phosphonopentanoic acid into the hippocampus, a profound increase in activity was observed in the open arms of an elevated plus-maze, strongly suggesting that the up-regulation of NMDA receptors due to the blockage in the hippocampus mediates an anxiolytic-like effect (Nascimento Häckl, Carobrez, 2007). The elevated plus-maze is a widely used animal model of anxiety that is based on two conflicting tendencies, namely the rodent’s drive to explore a novel environment and its aversion to open spaces. Thus, anxious animals will spend most of their time in the closed arms, whereas less anxious animals will explore open areas for longer period of time (Pellow et al., 1985). A similar result was also found in Raiennie’s study illustrating that long-lasting anxiety-like behavior in rats was eliminated by applying an NMDA receptor antagonist into the basolateral complex of the amygdala (Raiennie et al., 2004). It appears that treatment with an NMDA receptor antagonist such as dizocilpine in rodents could reduce anxiety behavior (Ma, Leung, 2007). Moreover, the anxiolytic effect obtained after the microinjection of spermine into the periaqueductal gray matter was blocked by pretreatment with a polyamines antagonist, such as arcaine or ifenprodil, at the same site (Cruz, Carobrez, 2006). These results demonstrate that other modulatory sites on the NMDA receptor complex may be targeted to alter anxiety in addition to direct antagonism of the NMDA pore region or glutamate-binding site. Reduction of the availability of NMDA receptors to interact with NMDA or its physiological ligand glutaatem is one mechanism that might mediate the anxiolytic activity of SIM. Our results also provide strong evidence that chronic high-dose SIM administration has NMDA antagonist-like effects, which would partially explain the anxiolytic effects of this drug (Camargo et al., 2013; Carrocini et al., 2012; Cruz et al., 2011; Pauleti et al., 2013; Santos et al., 2012).

SIM TREATMENT EXERTS ANXIOLYTIC-LIKE EFFECTS

Our results suggest that sub-chronic treatment with SIM reduced anxiety levels in male Wistar rats when combined with environmental enrichment (Cruz et al., 2011; Camargo et al., 2013). Music exposure combined with SIM treatment increased the percentage of time spent and entries into the open arms of the elevated plus-maze (Table 1). These two studies reached the same conclusion that SIM combined with music has anxiolytic-like effects in the elevated plus-maze. A possible mechanism mediating these effects could involve NMDA receptor modulation. These results indicate that music can serve as an effective adjuvant in rats treated with SIM and that this species could potentially be used in other pre-clinical models utilizing musical interventions (Cruz et al., 2015).

Prolonged administration of different classes of drugs may produce convergent effects on different neurotransmitter systems or signaling targets. Unfortunately, little information is available regarding neurotransmitter substrates that are critical for the behavioral effects of different types of drugs in animal models. In addition, data accumulated in the last decade indicate that NMDA receptors may be involved in the pathophysiology of depression and the mechanism of action of antidepressants (Szasz et al., 2007). These data suggest that the inhibitory effect of fluoxetine is exerted directly on NMDA receptors, contributing to the therapeutic effects of this drug. Pre-clinical data demonstrated that blocking the NMDA receptor complex...
produced anxiolytic and antidepressant activity in animal tests (Pittenger, Sanacora, Krystal, 2007; Riaza Bermudo-Soriano et al., 2012). The results of our experiments suggest that sub-chronic treatment with SIM reduces anxiety levels in rats when administered with fluoxetine (Santos et al., 2012). The experimental groups orally administered 10 mg/kg SIM combined with 10 mg/kg fluoxetine exhibited increased time spent in the open arms of the elevated plus-maze (Table II). These results strongly indicate that SIM treatment combined with fluoxetine improves the ability to cope with aversive situations, thus leading to a reduced anxiety level and playing an important role in the synergistic effect of combination therapy (Santos et al., 2012; Gougol et al., 2015). A possible mechanism mediating these effects may involve modulation of NMDA receptors by the cholesterol distribution within brain cell membranes (Kirsch, Eckert, Mueller, 2003; Ponce et al., 2008). However, the possible involvement of MLRs in NMDA receptor function and its modulation by fluoxetine could not be confirmed. In addition, the impairment of MLRs integrity by cholesterol depletion did not affect the modulatory potency of desipramine at the NMDA receptor, suggesting that the membrane localization of this receptor and compound plays a minor role for its modulation by this antidepressant (Nothdurfter et al., 2013).

Benzodiazepines are the most frequently used psychotropic agents and the mainstay of drug treatment for anxiety disorders. The elevated plus-maze test is a task that reliably detects the anxiolytic effect of clinically

### TABLE I – Effect of simvastatin (SIM, 1 and 10 mg/kg oral) on anxiety-like behavior in rats under each sound condition (silence and music) in the elevated plus-maze – percent time spent in the open arm and percent frequency of open arm entries. Values are expressed as the mean ± standard error of the mean; n = 10, *p<0.05, **p<0.01, and ***p<0.001. Statistically significant compared to the vehicle-silence group (analysis of variance [ANOVA] followed by the Newman-Keuls test)

| Treatment | %Time spent in the open arm (ANOVA → F = 4.160; p<0.01) | % Frequency of open arm entries (ANOVA → F = 5.483; p<0.001) |
|-----------|-----------------------------------------------------|----------------------------------------------------------|
| Silence   |                                                     |                                                         |
| Vehicle   | 11.5 ± 2.1                                          | 22.5 ± 6.2                                              |
| SIM 1 mg/kg | 16.6 ± 1.7                                         | 28.4 ± 6.6                                              |
| SIM 10 mg/kg | 33.1 ± 3.6                                        | 31.1 ± 6.4                                              |
| Music     |                                                     |                                                         |
| Vehicle   | 25.3 ± 2.9                                          | 28.6 ± 5.0                                              |
| SIM 1 mg/kg | 40.0 ± 5.2*                                        | 43.7 ± 4.7***                                           |
| SIM 10 mg/kg | 36.3 ± 3.0*                                       | 34.9 ± 4.9**                                            |

Source: (Camargo et al., 2013).

### TABLE II – Behavioral responses of rats in the elevated plus-maze following sub-chronic simvastatin (SIM) treatment combined with fluoxetine (Flu) - percent time spent in the open arm and percent frequency of open arm entries. Values are expressed as the mean ± standard error of the mean; n = 8, **p<0.01. Statistically significant compared to the vehicle group (analysis of variance [ANOVA] followed by the Newman-Keuls test)

| Treatment | %Time spent in the open arm (ANOVA → F = 4.979; p<0.001) | % Frequency of open arm entries (ANOVA → F = 2.207; p>0.05) |
|-----------|-----------------------------------------------------|----------------------------------------------------------|
| Vehicle   |                                                     |                                                         |
| SIM 1 mg/kg | 10.5 ± 5.0                                         | 48.0 ± 4.0                                              |
| SIM 10 mg/kg | 18.0 ± 7.0                                         | 56.5 ± 3.5                                              |
| Flu 2 mg/kg | 28.5 ± 2.0                                         | 54.8 ± 6.0                                              |
| SIM 1 mg/kg + Flu 2 mg/kg | 17.7 ± 8.0                                      | 51.7 ± 9.0                                              |
| SIM 10 mg/kg + Flu 2 mg/kg | 11.8 ± 2.0                                         | 42.1 ± 3.0                                              |
| Flu 10 mg/kg | 27.4 ± 3.0                                         | 54.8 ± 2.5                                              |
| SIM 1 mg/kg + Flu 10 mg/kg | 27.3 ± 9.0                                         | 53.3 ± 8.0                                              |
| SIM 10 mg/kg + Flu 10 mg/kg | 13.9 ± 4.0                                         | 41.8 ± 4.0                                              |
| SIM 10 mg/kg + Flu 10 mg/kg | 41.2 ± 7.0**                                       | 48.0 ± 4.5                                              |

Source: (Santos et al., 2012)
Simvastatin treatment reduces the cholesterol content of membrane/lipid rafts, implicating the N-methyl-D-aspartate receptor in anxiety.

Relevant benzodiazepines, such as diazepam that display anxiolytic-like behavioral profile including increases in the percentage of entries into and time spent in the open arms of the maze (Zhou et al., 2015). Our results suggest that sub-chronic treatment with SIM reduces anxiety levels in mice when combined with diazepam (Pauleti et al., 2013). Diazepam combined with SIM increases the percentage of time spent and entries into the open arms of the elevated plus-maze (Table III). Additionally, SIM could potentiate the anxiolytic-like effects of diazepam. In mammals, the involvement of excitatory glutamate and inhibitory gamma (γ)-aminobutyric acid (GABA) in the amygdala is particularly important for controlling levels of fear and anxiety (Bian, 2013). The NMDA receptor has also been directly implicated in the emergence of gamma rhythms, as NMDA receptor antagonists can disrupt or potentiate gamma rhythms in vivo (Pinault, 2008). Pre-synaptically, NMDA receptors may participate in neurotransmitter release, a process dependent on Ca\(^{2+}\) ions, whereas post-synaptically, their location on GABAergic neurons may contribute to the regulation of inhibitory tone and normal oscillatory activity in the brain (Deutsch et al., 2010). Therefore, NMDA receptors contribute to the regulation of central inhibitory tone by influencing the firing of GABA-inhibitory neurons. In addition to NMDA receptors, other receptors on the surface of GABA-inhibitory neurons may represent promising pharmacotherapeutic targets. Consistent with this hypothesis, blockade of the NMDA receptor complex and/or activation of benzodiazepine receptors mediated anxiolytic activity in elevated plus-maze tests induced, by the co-administration of SIM and diazepam. Additionally, the localization of NMDA receptors within the MLRs appears to depend on the respective GABA\(_A\) receptor subunit composition (Nothdurfter et al., 2013).

Several studies identified ethanol as a potent and selective inhibitor of NMDA receptors, and prolonged ethanol exposition leads to a compensatory up-regulation of these receptors, resulting in enhanced NMDA receptor-mediated functions after ethanol withdrawal. These alterations are believed to contribute to the development of ethanol tolerance and, dependence as well as the acute and delayed signs of ethanol withdrawal (Nagy, 2004). In particular, the up-regulation of different subunits of the NMDA receptor may cause hyperexcitability of the CNS during withdrawal or negative emotions such as dysphoria, irritability, anxiety, and depression (Blanco-Gandía et al., 2015). In accordance with numerous data in the literature, ethanol withdrawal induces an anxiogenic effect in the elevated plus-maze (Kumar et al., 2013; Van Skike, Diaz-Granados, Matthews, 2015). However, these findings contrast our previous data indicating that lower doses of ethanol produce anxiolytic-like effects (Cruz et al., 2012a). Therefore, negative modulators of NMDA receptors may be useful for the pharmacotherapy of alcoholism, attenuating both the physical symptoms and

| Treatment                  | %Time spent in the open arm (ANOVA → F = 6.858; p<0.001) | % Frequency of open arm entries (ANOVA → F = 9.614; p<0.001) |
|----------------------------|--------------------------------------------------------|-------------------------------------------------------------|
| Vehicle                    | 1.5 ± 0.5                                              | 3.2 ± 1.0                                                  |
| SIM 1 mg/kg                | 12.1 ± 1.0**                                           | 31.8 ± 4.5*                                               |
| SIM 10 mg/kg               | 10.0 ± 0.8**                                           | 14.0 ± 5.0                                                |
| DZP 0.5 mg/kg              | 28.9 ± 2.0**                                           | 52.2 ± 8.0**                                              |
| SIM 1 mg/kg + DZP 0.5 mg/kg| 27.8 ± 1.5**                                           | 48.1 ± 6.0**                                              |
| SIM 10 mg/kg + DZP 0.5 mg/kg| 41.6 ± 1.6**                                          | 52.4 ± 4.0**                                              |
| DZP 1 mg/kg                | 50.3 ± 2.0***                                          | 74.8 ± 11.0***                                            |
| SIM 1 mg/kg + DZP 1 mg/kg  | 57.0 ± 2.5***                                          | 45.4 ± 13.0**                                             |
| SIM 10 mg/kg + DZP 1 mg/kg | 88.6 ± 2.7***                                          | 92.5 ± 7.0***                                             |
| DZP 2 mg/kg                | 60.2 ± 3.0***                                          | 69.7 ± 6.8***                                             |
| SIM 1 mg/kg + DZP 2 mg/kg  | 57.0 ± 5.0***                                          | 60.2 ± 7.3***                                             |
| SIM 10 mg/kg + DZP 2 mg/kg | 73.4 ± 3.5***                                          | 75.6 ± 5.0***                                             |

Source: (Pauleti et al., 2013)
some affective and motivational components of alcohol withdrawal. The results of our experiments suggest that sub-chronic treatment with SIM reduces anxiety-like behavior in ethanol-withdrawn rats (Carrocini et al., 2012). These symptoms were observed as increases in the percentage of time spent in and entries into the open arms of the elevated plus-maze (Table IV). The evidence supporting the effects of SIM treatment on NMDA receptor binding density in the brain reveals a possible NMDA antagonist-like effect, which provides an exciting and potential paradigm for decreasing anxiety (Yan et al., 2011; Wang et al., 2009). Cholesterol depletion is reported to lead to an inhibition of Ca\textsuperscript{2+} entry induced by NMDA, AMPA, or kainate, inferring that MLRs contribute to the regulation of ionotropic glutamate receptor function (Frank et al., 2008). Therefore, treatment with SIM might affect the functionality of proteins associated with MLRs, such as NMDA receptors.

These findings will contribute to a better understanding of the critical roles of SIM in treating anxiety, demonstrating that reducing cholesterol levels protects against NMDA-induced anxiety, probably by suppressing the association of NMDA receptors with MLRs. Changes in brain cholesterol metabolism have been reported in experimental animals and humans, sometimes following short-term statin treatment. It is possible that SIM affects neuronal cholesterol levels soon after the beginning of treatment (Locatelli et al., 2002; Thelen et al., 2006).

**ORCHESTRATION OF NMDA RECEPTOR SIGNALING BY SIM**

Statins have been demonstrated to act through cholesterol-dependent and independent mechanisms, and they can affect several tissue functions and modulate specific signal transduction pathways that could explain their pleiotropic effects. Cholesterol appears to be essential for the stability and functionality of MLRs. The inhibition of HMG-CoA reductase by SIM disrupts the distribution of signaling molecules within rafts, resulting in a reduced association of an NMDA receptor subunit with MLRs, although no change was found in the total level of this NMDA receptor subunit (Kirsch, Eckert, Mueller, 2003; Ponce et al., 2008; Wang et al., 2009). As a possible mechanism of the anxiolytic-like effect of SIM based on our data, we propose that the reduction of the level of membrane cholesterol decreases transporter-mediated glutamate release from nerve terminals (Camargo et al., 2013; Carrocini et al., 2012; Cruz et al., 2011; Pauleti et al., 2013; Santos et al., 2012). This does not contradict the NMDA-dependent and non-sterol mechanisms of action of SIM (there may be additive or synergetic effect). It is well documented that NMDA receptors in the brain have a close correlation with anxiety-like activity (Bergink, van Megen, Westenberg, 2004; Réus et al., 2015). It is highly probable that inhibition of NMDA receptor down-regulation in the hippocampus and basolateral complex of the amygdala mediate the anxiolytic effects of SIM (Yan et al., 2011, Wang et al., 2009). Accordingly, NMDA, AMPA, and metabotropic glutamate receptors are regulated by MLRs-related pathways (Francesconi, Kumari, Zukin, 2009; Hou et al., 2008; Swanwick et al., 2009).

However, the cholesterol synthesis pathway also has several by-products, including non-sterol isoprenoids that are important in cellular functioning (McTaggart, 2006). The impact of SIM treatment on NMDA receptor function/trafficking is most likely related to its effects on protein prenylation, in particular protein farnesylation (Mans, Memahon, Li, 2012). It is worth noting that SIM treatment can enhance NMDA receptor activity by

**TABLE IV** - Behavioral responses in the elevated plus-maze following sub-chronic simvastatin (SIM) treatment in rats with ethanol (EtOH) withdrawal syndrome - percentage of time spent in the open arm and percentage of frequency of open arm entries. Values are expressed as the mean ± standard error of the mean; n = 10, *p<0.05. Statistically significant compared to the vehicle group (analysis of variance [ANOVA] followed by the Newman-Keuls test)

| Treatment          | %Time spent in the open arm (ANOVA → F = 3.183; p<0.05) | % Frequency of open arm entries (ANOVA → F = 1.469; p>0.05) |
|--------------------|---------------------------------------------------------|------------------------------------------------------------|
| Vehicle            | 6.9 ± 2.0                                               | 19.6 ± 3.8                                                 |
| SIM 1 mg/kg        | 18.6 ± 4.6*                                            | 25.9 ± 4.3                                                 |
| SIM 10 mg/kg       | 12.1 ± 2.8                                             | 32.7 ± 4.3                                                 |
| EtOH               | 4.0 ± 1.6                                              | 28.1 ± 4.0                                                 |
| SIM 1 mg/kg + EtOH | 23.4 ± 4.6*                                            | 30.9 ± 5.2                                                 |
| SIM 10 mg/kg + EtOH| 17.3 ± 4.9                                             | 22.1 ± 4.8                                                 |

Source: (Carrocini et al. (2012))
Simvastatin treatment reduces the cholesterol content of membrane/lipid rafts, implicating the N-methyl-D-aspartate receptor in anxiety

In this study, we reviewed the mechanism by which lipids change and affect this disorder will be of great benefit to biology and pharmacology in cases in which lipids and lipid-affecting drugs might be used as clinically. However, more evidence is required before any SIM therapy can be recommended clinically in the treatment or prevention of anxiety.

CONFLICT OF INTEREST

No conflict of interest has been declared.

REFERENCES

ALLEN, J.A.; HALVERSON-TAMBOLI, R.A.; RASENICK, M.M. Lipid raft microdomains and neurotransmitter signalling. Nat. Rev. Neurosci., v.8, n.2, p.128-140, 2007.

BARKUS, C.; MCHUGH, S.B.; SPRENGEL, R.; SEEBURG, P.H.; RAWLINS, J.N.; BANNERMAN, D.M. Hippocampal NMDA receptors and anxiety: at the interface between cognition and emotion. Eur. J. Pharmacol., v.626, n.1, p.49-56, 2010.

BERGINK, V.; VAN MEGEN, H.J.; WESTENBERG, H.G. Glutamate and anxiety. Eur. Neuropsychopharmacol., v.14, n.3, p.175-183, 2004.

BIAN, X. Physiological and morphological characterization of GABAergic neurons in the medial amygdala. Brain Res., v.1509, n.1, p.8-19, 2013.

BLANCO-GANDÍA, M.C.; MATEOS-GARCÍA, A.; GARCÍA-PARDO, M.P.; MONTAGUD-ROMERO, S.; RODRÍGUEZ-ARIAS, M.; MIÑARRO, J.; AGUILAR, M.A. Effect of drugs of abuse on social behaviour: a review of animal models. Behav. Pharmacol., v.26, n.6, p.541-570, 2015.

BLUNDELL, J.; ADAMEC, R. The NMDA receptor antagonist CPP blocks the effects of predator stress on pCREB in brain regions involved in fearful and anxious behavior. Brain Res., v.1136, n.1, p.59-76, 2007.

BYRUM, J.N.; RODGERS, W. Membrane-cytoskeleton interactions in cholesterol-dependent domain formation. Essays Biochem., v.57, n.1, p.177-187, 2015.

CAMARGO, A.M.; LIMA, D.D.; DAL MAGRO, D.D.; SEUBERT, J.K.; CRUZ, J.N.; CRUZ, J.G. Adjuvant effects of classical music on simvastatin induced reduction of anxiety but not object recognition memory in rats. Psychol. Neurosci., v.6, n.1, p.403-410, 2013.

reducing FPP levels (Chen et al., 2016; Mans, Memahon, Li, 2012; Parent et al., 2014). These data strongly implicate SIM-induced changes in neuronal function via isoprenoid-mediated modulation of small GTPases. Indeed, activation of the small GTPase H-Ras, which depends on farnesylation for function, decreases the surface distribution of the NR2 subunit of the NMDA receptor (Suvarna et al., 2005). Accordingly, deletion of H-Ras increases NMDA receptor-dependent synaptic conductance (Manabe et al., 2000).

Studies supporting the isoprenoid hypothesis were performed using extremely high statin concentrations; thus, their clinical significance is debatable. The question whether inhibition of prenylation occurs in the brain therefore remains open. On the contrary, although the effect of statins on the peripheral pool of cholesterol is well-established, their effects on CNS cholesterol are less clear. The CNS does not rely largely on cholesterol from systemic circulation due to limited metabolic turnover during adulthood and the brain’s inherent capacity to synthesize its own cholesterol (Dietschy, Turley, 2004). As such, reductions in plasma cholesterol concentrations following statin treatment are unlikely to acutely disrupt in CNS cholesterol homeostasis (Lutjohann et al., 2004; Thelen et al., 2006). Unlike cholesterol in plasma, which has a half-life of only a few days, brain cholesterol has a half-life of 6 months to 5 years (Dietschy, Turley, 2004). Thus, chronic statin therapy may be required before significant effects on CNS cholesterol are observed, with reductions in CNS cholesterol content possibly occurring either directly through direct HMG-CoA reductase inhibition or indirectly via a “sink effect” (Cibičková, 2011). There exists much controversy regarding the effects of statins on neuronal function (Cruz et al., 2012b). We believe that more detailed research into the pharmacology of statins, particularly compared to the well-established, their effects on CNS cholesterol are less clear. The CNS does not rely largely on cholesterol from systemic circulation due to limited metabolic turnover during adulthood and the brain’s inherent capacity to synthesize its own cholesterol (Dietschy, Turley, 2004).

As such, reductions in plasma cholesterol concentrations following statin treatment are unlikely to acutely disrupt in CNS cholesterol homeostasis (Lutjohann et al., 2004; Thelen et al., 2006). Unlike cholesterol in plasma, which has a half-life of only a few days, brain cholesterol has a half-life of 6 months to 5 years (Dietschy, Turley, 2004). Thus, chronic statin therapy may be required before significant effects on CNS cholesterol are observed, with reductions in CNS cholesterol content possibly occurring either directly through direct HMG-CoA reductase inhibition or indirectly via a “sink effect” (Cibičková, 2011). There exists much controversy regarding the effects of statins on neuronal function (Cruz et al., 2012b). We believe that more detailed research into the pharmacology of statins, particularly during adulthood and the brain’s inherent capacity to synthesize its own cholesterol (Dietschy, Turley, 2004).

In summary, if our speculation is correct, this finding presents a novel point that sub-chronic treatment with SIM results in an anxiolytic effect, probably by reducing the association of NMDA receptors with MLRs. These novel results could have significant implications for our understanding of the influence of cholesterol-lowering agents such as SIM on the organization and function of the NMDA receptor, an important neurotransmitter receptor. In this study, we reviewed the mechanism by which membrane lipids, which play roles in the membrane’s function as a barrier and signaling medium, contribute to anxiety. Understanding the molecular mechanisms by which lipids change and affect this disorder will be...
CARROCINI, M.M.; CAXAMBÚ, A.L.; KELLE, N.S.; LIMA, D.D.; CRUZ, J.N.; DAL MAGRO, D.D.; CRUZ, J.G. Chronic simvastatin treatments attenuate ethanol withdrawal syndrome in rats. *Am. J. Med. Med. Sci.*, v.2, n.2, p.22-28, 2012.

CHEN, T.; ZHANG, B.; LI, G.; CHEN, L.; CHEN, L. Simvastatin enhances NMDA receptor GluN2B expression and phosphorylation of GluN2B and GluN2A through increased histone acetylation and Src signaling in hippocampal CA1 neurons. *Neuropharmacology*, v.107, n.1, p.411-421, 2016.

CHEN, J.; ZHANG, Z.G.; LI, Y.; WANG, Y.; WANG, L.; JIANG, H.; ZHANG, C.; LU, M.; KATAKOWSKI, M.; FELDKAMP, C.S.; CHOPP, M. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. *Ann. Neurol.*, v.53, n.6, p.743-751, 2003.

CHOBANIAN, A.V.; HOLLANDER, W. Body cholesterol metabolism in man. I. The equilibration of serum and tissue cholesterol. *J. Clin. Invest.*, v.41, n.1, p.1732-1737, 1962.

CHOJNACKA-WÓJCIK, E.; KŁODZINSKA, A.; PILC, A. Glutamate receptor ligands as anxiolytics. *Curr. Opin. Investig. Drugs*, v.2, n.8, p.1112-1119, 2001.

CIBIČKOVÁ, L. Statins and their influence on brain cholesterol. *J. Clin. Lipidol.*, v.5, n.5, p.373-379, 2011.

CRUZ, J.N.; TOMASI, C.D.; ALVES, S.C.; MACEDO, R.C.; GIOMBELLI, V.; CRUZ, J.G.; DAL-PIZZOL, F.; RITTER, C. The incidence of delirium in patients pretreated with statins who remain in an intensive care unit after cardiac surgery. *Rev. Bras. Ter. Intensiva*, v.24, n.1, p.52-57, 2012b.

CRUZ, J.N.; LIMA, D.D.; DAL MAGRO, D.D.; CRUZ, J.G. The power of classic music to reduce anxiety in rats treated with simvastatin. *Basic Clin. Neurosci.*, v.2, n.4, p.5-11, 2011.

CRUZ, J.N.; LIMA, D.D.; DAL MAGRO, D.D.; CRUZ, J.G. Anxiolytic effects of swimming exercise and ethanol in two behavioral models: beneficial effects and increased sensitivity in mice. *Rev. Ciênc. Farm. Básica Apl.*, v.33, n.1, p.115-123, 2012a.

CRUZ, J.N.; LIMA, D.D.; DAL MAGRO, D.D.; CRUZ, J.G. Anxiolytic effect of Mozart music over short and long photoperiods as part of environmental enrichment in captive Rattusnorvegicus (Rodentia: Muridae). *Scand. J. Lab. Anim. Sci.*, v.41, n.7, p.1-7, 2015.

CRUZ, J.N.; TOMASI, C.D.; ALVES, S.C.; MACEDO, R.C.; GIOMBELLI, V.; CRUZ, J.G.; DAL-PIZZOL, F.; RITTER, C. The incidence of delirium in patients pretreated with statins who remain in an intensive care unit after cardiac surgery. *Rev. Bras. Ter. Intensiva*, v.24, n.1, p.52-57, 2012b.

DANESCHVAR, H.L.; ARONSON, M.D.; SMETANA, G.W. Do statins prevent Alzheimer’s disease? a narrative review. *Eur. J. Intern. Med.*, v.26, n.9, p.666-669, 2015.

DEUTSCH, S.I.; ROSSE, R.B.; SCHWARTZ, B.L.; MASTROPAOLO, J.; BURKET, J.A.; WEIZMAN, A. Regulation of intermittent oscillatory activity of pyramidal cell neurons by GABA inhibitory interneurons is impaired in schizophrenia: rationale for pharmacotherapeutic GABAergic interventions. *Isr. J. Psychiatry Relat. Sci.*, v.47, n.1, p.17-26, 2010.

DIETSCHY, J.M.; TURLEY, S.D. Thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. *J. Lipid Res.*, v.45, n.8, p.1375-1397, 2004.

DUPREE, J.L.; POMICTER, A.D. Myelin, DIGs, and membrane rafts in the central nervous system. *Prostaglandins Other Lipid Mediat.*, v.91, n.3/4, p.118-129, 2010.

DUTTA, A.; KRIEGER, J.; LEE, J.Y.; GARCIA-NAFRIA, J.; GREGER, I.H.; BAHAR, I. Cooperative dynamics of intact AMPA and NMDA glutamate receptors: Similarities and subfamily-specific differences. *Structure*, v.23, n.9, p.1692-1704, 2015.

EGAWA, J.; PEARN, M.L.; LEMKUIL, B.P.; PATEL, P.M.; HEAD, B.P. Membrane/lipid rafts and neurobiology: age-related changes in membrane lipids and loss of neuronal function. *J. Physiol.*, v.594, n.16, p.4565-4579, 2016.

EGER, G.A.; FERREIRA, V.V.; BATISTA, C.R.; BONDE, H.; LIMA, D.D.; RODRIGUES, A.F.; CRUZ, J.G.; DAL MAGRO, D.D. Acute administration of diazepam provokes redox homeostasis imbalance in the rat brain: prevention by simvastatin. *J. Biochem. Mol. Toxicol.*, v.30, n.10, p.506-512, 2016a.

EGER, G.A.; FERREIRA, V.V.; BATISTA, C.R.; BONDE, H.; LIMA, D.D.; RODRIGUES, A.F.; CRUZ, J.G.; DAL MAGRO, D.D.; CRUZ, J.G. Antioxidant effect of simvastatin throught oxidative imbalance caused by lisdexamfetaminedimesylate. *An. Acad. Bras. Ciênc.*, v.88, n.1, p.335-348, 2016b.
Simvastatin treatment reduces the cholesterol content of membrane/lipid rafts, implicating the N-methyl-D-aspartate receptor in anxiety

EPAND, R.M. Proteins and cholesterol-rich domains. Biochim. Biophys. Acta., v.1778, n.7/8, p.1576-1582, 2008.

ESCRIBÁ, P.V.; BUSQUETS, X.; INOKUCHI, J.; BALOGH, G.; TÖRÖK, Z.; HORVÁTH, I.; HARWOOD, J.L.; VÍGH, L. Membrane lipid therapy: modulation of the cell membrane composition and structure as a molecular base for drug discovery and new disease treatment. Prog. Lipid. Res., v.59, n.1, p.38-53, 2015.

FIELDING, C.J.; FIELDING, P.E. Relationship between cholesterol trafficking and signaling in rafts and caveolae. Biochim. Biophys. Acta., v.1610, n.2, p.219-228, 2003.

FRANCESCONI, A.; KUMARI, R.; ZUKIN, R.S. Regulation of group I metabotropic glutamate receptor trafficking and signaling by the caveolar/lipid raft pathway. J. Neurosci., v.29, n.11, p.3590-3602, 2009.

FRANK, C.; RUFINI, S.; TANCREDI, V.; FORCINA, R.; GROSSI, D.; D’ARCANGELO, G. Cholesterol depletion inhibits synaptic transmission and synaptic plasticity in rat hippocampus. Exp. Neurol., v.212, n.2, p.407-414, 2008.

FRIEDMAN, B.; LAHAD, A.; DRESNER, Y.; VINKER, S. Long-term statin use and the risk of Parkinson’s disease. Am. J. Manag. Care, v.19, n.8, p.626-632, 2013.

GALLALA, H.D.; BREIDEN, B.; SANDHOFF, K. Regulation of the NPC2 protein-mediated cholesterol trafficking by membrane lipids. J. Neurochem., v.116, n.5, p.702-707, 2011.

GOUGOL, A.; ZAREH-MOHAMMADI, N.; RAHEB, S.; FAROKHNIA, M.; SALIMI, S.; IRANPOUR, N.; YEKEHTAZ, H.; AKHONDZADEH, S. Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: a double-blind placebo-controlled trial. J. Psychopharmacol., v.29, n.5, p.575-581, 2015.

GRASSME, H.; JEKLE, A.; RIEHLE, A.; SCHWARZ, H.; BERGER, J.; SANDHOFF, K.; KOLESNICK, R.; GULBINS, E. CD95 signaling via ceramide-rich membrane rafts. J. Biol. Chem., v.276, n.23, p.20589-20596, 2001.

HANZAL-BAYER, M.F.; HANCOCK, J.F. Lipid rafts and membrane traffic. FEBS Lett., v.581, n.11, p.2098-2104, 2007.

HELMS, J.B.; ZURZOLO, C. Lipids as targeting signals: lipid rafts and intracellular trafficking. Traffic., v.5, n.4, p.247-254, 2004.

HIROSE, T.; SAIKI, R.; YOSHIZAWA, Y.; IMAMURA, M.; HIGASHI, K.; ISHII, I.; TOIDA, T.; WILLIAMS, K.; KASHIWAGI, K.; IGARASHI, K. Spermidine and Ca(2+), but not Na(+), can permeate NMDA receptors consisting of GluN1 and GluN2A or GluN2B in the presence of Mg(2+). Biochem. Biophys. Res. Commun., v.463, n.4, p.190-195, 2015.

HOU, Q.; HUANG, Y.; AMATO, S.; SNYDER, S.H.; HUGANIR, R.L.; MAN, H.Y. Regulation of AMPA receptor localization in lipid rafts. Mol. Cell Neurosci., v.38, n.2, p.213-223, 2008.

HOUTEN, S.M.; FRENKEL, J.; WATERHAM, H.R. Isoprenoid biosynthesis in hereditary periodic fever syndromes and inflammation. Cell Mol. Life Sci., v.60, n.6, p.1118-1134, 2003.

KARASINSKA, J.M.; HAYDEN, M.R. Cholesterol metabolism in Huntington disease. Nat. Rev. Neuroul., v.7, n.10, p.561-572, 2011.

KATAOKA, Y.; HAMMADAH, M.; PURI, R.; DUGGAL, B.; UNO, K.; KAPADIA, S.R.; MURAT TUZCU, E.; NISSEN, S.E.; NICHOLLS, S.J. Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels. Atherosclerosis, v.242, n.2, p.490-495, 2015.

KILIC, F.S.; OZATIK, Y.; KAYGISIZ, B.; BAYDEMIR, C.; EROL, K. Acute antidepressant and anxiolytic effects of simvastatin and its mechanisms in rats. Neurosci. (Riyadh), v.17, n.1, p.39-43, 2012.

KIRSCH, C.; ECKERT, G.P.; MUELLER, W.E. Statin effects on cholesterol micro-domains in brain plasma membranes. Biochem. Pharmacol., v.65, n.5, p.843-856, 2003.

KORADE, Z.; KENWORTHY, A.K. Lipid rafts, cholesterol, and the brain. Neuropharmacology, v.55, n.8, p.1265-1273, 2008.

KOTTI, T.J.; RAMIREZ, D.M.; PFEIFFER, B.E.; HUBER, K.M.; RUSELL, D.W. Brain cholesterol turnover required for geranylgeraniol production and learning in mice. Proc. Natl. Acad. Sci. U.S.A., v.103, n.10, p.3869-3874, 2006.
KUMAR, J.; HAPIDIN, H.; BEE, Y.T.; ISMAIL, Z. Effects of the mGluR5 antagonist MPEP on ethanol withdrawal induced anxiety-like syndrome in rats. *Behav. Brain Funct.*, v.9, n.1, p.1-13, 2013.

KUMARI, R.; CASTILLO, C.; FRANCESCONI, A. Agonist-dependent signaling by group I metabotropic glutamate receptors is regulated by association with lipid domains. *J. Biol. Chem.*, v.288, n.44, p.32004-32019, 2013.

LEE, A.G. How lipids affect the activities of integral membrane proteins. *Biochim. Biophys. Acta*, v.1666, n.1/2, p.62-87, 2004.

LOCATELLI, S.; LÜTJOHANN, D.; SCHMIDT, H.H.; OTTO, C.; BEISIEGEL, U.; VON BERGMANN, K. Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain. *Arch. Neurol.*, v.59, n.2, p.213-216, 2002.

LUTJOHANN, D.; STROICK, M.; BERTSCH, T.; KUHL, S.; LINDENTHAL, B.; THELEN, K.; ANDERSSON, U.; BJORKHEM, I.; VON BERGMANN, K.; FASSBENDER, K. High doses of simvastatin, pravastatin and cholesterol reduce brain cholesterol synthesis in guinea pigs. *Steroids*, v.69, n.6, p.431-438, 2004.

MA, J.; LEUNG, L.S. The supramammillo-septal-hippocampal pathway mediates sensorimotor gating impairment and hyperlocomotion induced by MK-801 and ketamine in rats. *Psychopharmacology (Berl)*, v.191, n.4, p.961-974, 2007.

MANABE, T.; AIBA, A.; YAMADA, A.; ICHISE, T.; SAKAGAMI, H.; KONDO, H.; KATSUKI, M. Regulation of long-term potentiation by H-Ras through NMDA receptor phosphorylation. *J. Neurosci.*, v.20, n.7, p.2504-2511, 2000.

MANS, R.A.; MCMAHON, L.L.; LI, L. Simvastatin-mediated enhancement of long-term potentiation is driven by farnesyl-pyrophosphate depletion and inhibition of farnesylase. *Neuroscience*, v.202, n.1, p.1-9, 2012.

MARQUES-DA-SILVA, D.; GUTIERREZ-MERINO, C. L-type voltage-operated calcium channels, N-methyl-D-aspartate receptors and neuronal nitric-oxide synthase form a calcium/redox nano-transducer within lipid rafts. *Biochem. Biophys. Res. Commun.*, v.420, n.2, p.257-262, 2012.

MARQUES-DA-SILVA, D.; GUTIERREZ-MERINO, C. Caveolin-rich lipid rafts of the plasma membrane of mature cerebellar granule neurons are microcompartments for calcium/reactive oxygen and nitrogen species cross-talk signaling. *Cell Calcium*, v.56, n.2, p.108-123, 2014.

MARWALL, M.R.; REY-LADINO, J.; DREOLINI, L.; SHAW, D.; TAKEI, F. Membrane cholesterol regulates LFA-1 function and lipid raft heterogeneity. *Blood*, v.102, n.1, p.215-222, 2003.

MASNEUF, S.; LOWERY-GIONTA, E.; COLACICCO, G.; PLEIL, K.E.; LI, C.; CROWLEY, N.; FLYNN, S.; HOLMES, A.; KASH, T. Glutamatergic mechanisms associated with stress-induced amygdala excitability and anxiety-related behavior. *Neuropharmacology*, v.85, n.1, p.190-197, 2014.

MATHEWS, E.S.; MAWDSLEY, D.J.; WALKER, M.; HINES, J.H.; POZZOLI, M.; APPEL, B. Mutation of 3-hydroxy-3-methylglutaryl CoA synthase I reveals requirements for isoprenoid and cholesterol synthesis in oligodendrocyte migration arrest, axon wrapping, and myelin gene expression. *J. Neurosci.*, v.34, n.9, p.3402-3412, 2014.

MCTAGGART, S.J. Isoprenylated proteins. *Cell Mol. Life Sci.*, v.63, n.3, p.255-267, 2006.

MICHEL, V.; BAKOVIC, M. Lipid rafts in health and disease. *Biol. Cell*, v.99, n.3, p.129-140, 2007.

MIHOS, C.G.; PINEDA, A.M.; SANTANA, O. Cardiovascular effects of statins, beyond lipid-lowering properties. *Pharmacol. Res.*, v.88, n.1, p.12-19, 2014.

MOTHET, J.P.; LE BAIL, M.; BILLARD, J.M. Time and space profiling of NMDA receptor co-agonist functions. *J. Neurochem.*, v.135, n.2, p.210-225, 2015.

NASCIMENTO HäCKL, L.P.; CAROBREZ, A.P. Distinct ventral and dorsal hippocampus AP5 anxiolytic effects revealed in the elevated plus-maze task in rats. *Neurobiol. Learn. Mem.*, v.88, n.2, p.177-185, 2007.
NAGY, J. The NR2B subtype of NMDA receptor: a potential target for the treatment of alcohol dependence. *Curr. Drug Targets CNS Neurol. Disord.*, v.3, n.3, p.169-179, 2004.

NÍ CHRÓINÍN, D.; ASPLUND, K.; ÅSBERG, S.; CALLALY, E.; CUADRADO-GODIA, E.; DÍEZ-TEJEDOR, E.; DI NAPOLI, M.; ENGELTER, S.T.; FORIE, K.L.; GIANNOPoulos, S.; GOTTO Jr., A.M.; HANNON, N.; JONSSON, F.; KAPRAL, M.K.; MARTÍ-FÀBREGAS, J.; MARTÍNEZ-SÁNCHEZ, P.; MILIONIS, H.J.; MONTANER, J.; MUSCARI, A.; PIKJIA, S.; PROBSTFIELD, J.; ROST, N.S.; THRIFT, A.G.; VEMMOS, K.; KELLY, P.J. Statin therapy and outcome after ischemic stroke: systematic review and meta-analysis. *Stroke*, v.44, n.2, p.448-456, 2013.

NIEWEG, K.; SCHALLER, H.; PFRIEGER, F.W. Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats. *J. Neurochem.*, v.109, n.1, p.125-134, 2009.

NOTHDURFTER, C.; TANASIC, S.; DI BENEDETTO, B.; UHR, M.; WAGNER, E.M.; GILLING, K.E.; PARSONS, C.G.; REIN, T.; HOLZBOER, F.; RUPPRECHT, R.; RAMMES, G. Lipid raft integrity affects GABA receptors, but not NMDA receptor modulation by psychopharmacological compounds. *Int. J. Neuropsychopharmacol.*, v.16, n.6, p.1361-1371, 2013.

OWENS, A.P.; BYRNEs, J.R.; MACKMAN, N. Hyperlipidemia, tissue factor, coagulation, and simvastatin. *Trends Cardiovasc. Med.*, v.24, n.3, p.95-98, 2014.

PANI, B.; SINGH, B.B. Lipid rafts/caveolae as microdomains of calcium signaling. *Cell Calcium*, v.45, n.6, p.625-633, 2009.

PARENT, M.A.; HOTTMAN, D.A.; CHENG, S.; ZHANG, W.; McMHAON, L.L.; YUAN, L.L.; LI, L. Simvastatin treatment enhances NMDAR-mediated synaptic transmission by upregulating the surface distribution of the GluN2B subunit. *Cell Mol. Neurobiol.*, v.34, n.5, p.693-705, 2014.

PAULETTI, N.N.; COSTA, A.S.; LIMA, D.D.; DAL MAGRO, D.D.; CRUZ, J.N.; CRUZ, J.G. Behavioral interactions of simvastatin and diazepam in tests of anxiety and object recognition. *Am. J. Med. Med. Sci.*, v.3, n.6, p.178-189, 2013.

PELLOW, S.; CHOPIN, P.; FILE, S.E.; BRILEY, M. Validation of open: closed arm entries in the elevated plus-maze as a measure of anxiety in the rat. *J. Neurosci. Methods*, v.14, n.3, p.149-167, 1985.

PIHL-JENSEN, G.; TSAKIRI, A.; FREDERIKSEN, J.L. Statin treatment in multiple sclerosis: a systematic review and meta-analysis. *CNS Drugs*, v.29, n.4, p.277-91, 2015.

PINAULT, D. N-methyl d-aspartate receptor antagonists ketamine and MK-801 induce wake-related aberrant gamma oscillations in the rat neocortex. *Biol. Psychiatry*, v.63, n.8, p.730-735, 2008.

PITTENGER, C.; SANACORA, G.; KRYSsTAL, J.H. The NMDA receptor as a therapeutic target in major depressive disorder. *CNS Neurol. Disord. Drug Targets*, v.6, n.2, p.101-115, 2007.

PONCE, J.; DE LA OSSA, N.P.; HURTADO, O.; MILLAN, M.; ARENILLAS, J.F.; DÁVALOS, A.; GASULL, T. Simvastatin reduces the association of NMDA receptors to lipid rafts: a cholesterol-mediated effect in neuroprotection. *Stroke*, v.39, n.4, p.1269-1275, 2008.

RAINNIE, D.G.; BERGERON, R.; SAJDYK, T.J.; PATIL, M.; GEHLERT, D.R.; SHEKHAR, A. Corticotrophin releasing factor-induced synaptic plasticity in the amygdala translates stress into emotional disorders. *J. Neurosci.*, v.24, n.14, p.3471-349, 2004.

RESH, M.D. Membrane targeting of lipid modified signal transduction proteins. *Subcell Biochem.*, v.37, n.1, p.217-232, 2004.

RÉUS, G.Z.; ABALEIRA, H.M.; MICHELS, M.; TOMAZ, D.B.; DOS SANTOS, M.A.; CARLESSI, A.S.; MATIAS, B.I.; LEFFA, D.D.; DAMIANI, A.P.; GOMES V.C.; ANDRADE, V.M.; DAL-PIZZOL, F.; LANDEIRA-FERNÁDEZ, J.; QUEVEDO, J. Anxious phenotypes plus environmental stressors are related to brain DNA damage and changes in NMDA receptor subunits and glutamate uptake. *Mutat. Res.*, v.772, n.1, p.30-37, 2015.

RIAZA BERMUDO-SORIANO, C.; PEREZ-RODRIGUEZ, M.M.; VAQUERO-LORENZO, C.; BACA-GARCIA, E. New perspectives in glutamate and anxiety. *Pharmacol. Biochem. Behav.*, v.100, n.4, p.752-774, 2012.
RUOCCO, A.; SANTILLO, M.; CICALE, M.; SERU, R.; CUDA, G.; ANRATHER, J.; IADECOLA, C.; POSTIGLIONE, A.; AVVEDIMENTO, E.V.; PATERNÔ, R. Farnesyl transferase inhibitors induce neuroprotection by inhibiting Ha-Ras signalling pathway. *Eur. J. Neurosci.* v.26, n.11, p.3261-3266, 2007.

SABER, G.; STUMPF, S.K. Cholesterol in myelin biogenesis and hypomyelinating disorders. *Biochim. Biophys. Acta*, v.1851, n.8, p.1083-1094, 2015.

SANTOS, T.; BAUNGRATZ, M.M.; HASKEL, S.P.; DE LIMA, D.D.; DA CRUZ, J.N.; MAGRO, D.D.; DA CRUZ, J.G. Behavioral interactions of simvastatin and fluoxetine in tests of anxiety and depression. *Neuropsychiatr. Dis. Treat.*, v.8, n.1, p.13-22, 2012.

SEBASTIÃO, A.M.; COLINO-OLIVEIRA, M.; ASSAIFE-LOPES, N.; DIAS, R.B.; RIBEIRO, J.A. Lipid rafts, synaptic transmission and plasticity: impact in age-related neurodegenerative diseases. *Neuropharmacology*, v.64, n.1, p.97-107, 2013.

SEGATTO, M.; DI GIOVANNI, A.; MARINO, M.; PALLOTTINI, V. Analysis of the protein network of cholesterol homeostasis in different brain regions: an age and sex dependent perspective. *J. Cell Physiol.*, v.228, n.7, p.1561-1567, 2013.

SEONG, H.J.; BEHNIA, R.; CARTER, A.G. Impact of subthreshold membrane potential on synaptic responses at dendritic spines of layer 5 pyramidal neurons in the prefrontal cortex. *J. Neurophysiol.*, v.111, n.10, p.1960-1972, 2014.

SERRANO-POZO, A.; VEGA, G.L.; LÜTJOHANN, D.; LOCASCIO, J.J.; TENNIS, M.K.; DENG, A.; ATRI, A.; HYMAN, B.T.; IRIZARRY, M.C.; GROWDON, J.H. Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers. *Alzheimer Dis. Assoc. Disord.*, v.24, n.3, p.220-226, 2010.

SETT, A.K.; ROBINSON, T.G.; MISTRI, A.K. Current status of statin therapy for stroke prevention. *Expert. Rev. Cardiovasc. Ther.*, v.9, n.10, p.1305-1314, 2011.

SIMONS, K.; TOOMRE, D. Lipid rafts and signal transduction. *Nat. Rev. Mol. Cell Biol.*, v.1, n.1, p.31-39, 2000.

SIRRIEH, R.E.; MACLEAN, D.M.; JAYARAMAN, V. Subtype-dependent N-methyl-D-aspartate receptor amino-terminal domain conformations and modulation by spermine. *J. Biol. Chem.*, v.290, n.20, p.12812-12820, 2015.

SUVARNA, N.; BORGGLAND, S.L.; WANG, J.; PHAMLUONG, K.; AUBERSON, Y.P.; BONCI, A.; RON, D. Ethanol alters trafficking and functional N-methyl-D-aspartate receptor NR2 subunit ratio via H-Ras. *J. Biol. Chem.*, v.280, n.36, p.31450-31459, 2005.

SWANWICK, C.C.; SHAPIRO, M.E.; YI, Z.; CHANG, K.; WENTHOLD, R.J. NMDA receptors interact with flotillin-1 and -2, lipid raft-associated proteins. *FEBS Lett.*, v.583, n.8, p.1226-1230, 2009.

SZASZ, B.K.; MIKE, A.; KAROLY, R.; GEREVICH, Z.; ILLES, P.; VIZI, E.S.; KISS, J.P. Direct inhibitory effect of fluoxetine on N-methyl-D-aspartate receptors in the central nervous system. *Biol. Psychiatry*, v.62, n.11, p.1303-1309, 2007.

THELEN, K.M.; RENTSCH, K.M.; GUTTECK, U.; HEVERIN, M.; OLIN, M.; ANDERSSON, U.; VON ECKARDSTEIN, A.; BJÖRKHEM, I.; LÜTJOHANN, D. Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin. *J. Pharmacol. Exp. Ther.*, v.316, n.3, p.1146-1152, 2006.

UNGUREANU, D.; FILIP, C.; ARTEMIE, A.; ARTEMIE, R. Evaluation of simvastatin antioxidant effects. *Rev. Med. Chir. Soc. Med. Nat. Iasi.*, v.107, n.1, p.66-71, 2003.

VAN DER MOST, P.J.; DOLGA, A.M.; NIJHOLT, I.M.; LUITEN, P.G.; EISEL, U.L. Statins: mechanisms of neuroprotection. *Prog. Neurobiol.*, v.88, n.1, p.64-75, 2009.

VAN SKIKE, C.E.; DIAZ-GRANADOS, J.L.; MATTHEWS, D.B. Chronic intermittent ethanol exposure produces persistent anxiety in adolescent and adult rats. *Alcohol Clin. Exp. Res.*, v.39, n.2, p.262-271, 2015.

WANG, Q.; ZENGIN, A.; DENG, C.; LI, Y.; NEWELL, K.A.; YANG, G.Y.; LU, Y.; WILDER-SMITH, E.P.; ZHAO, H.; HUANG, X.F. High dose of simvastatin induces hyperlocomotive and anxiolytic-like activities: The association with the up-regulation of NMDA receptor binding in the rat brain. *Exp. Neurol.*, v.216, n.1, p.132-138, 2009.
Simvastatin treatment reduces the cholesterol content of membrane/lipid rafts, implicating the N-methyl-D-aspartate receptor in anxiety

Braz. J. Pharm. Sci. 2017;53(1):e16102

WU, H.; LU, D.; JIANG, H.; XIONG, Y.; QU, C.; LI, B.; MAHMOOD, A.; ZHOU, D.; CHOPP, M. Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K/Akt pathway, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury. *J. Neurotrauma*, v.25, n.2, p.130-139, 2008.

YAN, J.; XU, Y.; ZHU, C.; ZHANG, L.; WU, A.; YANG, Y.; XIONG, Z.; DENG, C.; HUANG, X.F.; YENARI, M.A.; YANG, Y.G.; YING, W.; WANG, Q. Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responses. *PLoS One*, v.6, n.6, art.e20945, p.1-13, 2011.

ZACCO, A.; TOGO, J.; SPENCE, K.; ELLIS, A.; LLOYD, D.; FURLONG, S.; PISER, T. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. *J. Neurosci.*, v.23, n.35, p.11104-11111, 2003.

ZHANG, Y.; LI, X.; BECKER, K.A.; GULBINS, E. Ceramide-enriched membrane domains - structure and function. *Biochim. Biophys. Acta.*, v.1788, n.1, p.178-183, 2009.

ZHANG, A.Y.; YI, F.; ZHANG, G.; GULBINS, E.; LI, P.L. Lipid raft clustering and redox signaling platform formation in coronary arterial endothelial cells. *Hypertension*, v.47, n.1, p.74-80, 2006.

ZOU, H.; YU, C.L.; WANG, L.P.; YANG, Y.X.; MAO, R.R.; ZHOU, Q.X.; XU, L. NMDA and D1 receptors are involved in one-trial tolerance to the anxiolytic-like effects of diazepam in the elevated plus maze test in rats. *Pharmacol. Biochem. Behav.*, v.135, n.1, p.40-45, 2015.

Received for publication on 07th June 2016
Accepted for publication on 19th October 2016